Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
This article was originally published in The Pink Sheet Daily
Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.
You may also be interested in...
Austerity Holds Back VC Investing in European Biotech Companies in 2011
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.